Financial Performance - For the year ended December 31, 2023, the total revenue was HKD 34,333,000, a decrease of 48.3% compared to HKD 66,489,000 in 2022[4] - The gross profit for the same period was HKD 14,808,000, slightly up from HKD 14,688,000 in 2022, indicating a stable gross margin despite lower revenue[4] - The net loss attributable to the company's owners was HKD 2,753,000, significantly improved from a loss of HKD 104,251,000 in the previous year, representing a reduction of 97.4%[5] - Revenue from continuing operations decreased to HKD 34,333 thousand in 2023 from HKD 66,489 thousand in 2022, representing a decline of 48.3%[25] - The reported segment performance improved to a profit of HKD 8,382 thousand in 2023 compared to a loss of HKD 70,125 thousand in 2022[25] - The company reported a loss before tax from continuing operations of HKD 1,713 thousand in 2023, significantly improved from a loss of HKD 104,293 thousand in 2022[25] - The company reported a significant reduction in total liabilities from HKD 151,765 thousand in 2022 to HKD 105,753 thousand in 2023, a decrease of 30.4%[25] - The group recorded realized and unrealized losses of approximately HKD 8,500,000 from trading investments in listed securities for the year ending December 31, 2023, compared to a loss of HKD 4,600,000 in 2022[93] Assets and Equity - The total assets as of December 31, 2023, were HKD 168,718,000, compared to HKD 166,494,000 in 2022, showing a slight increase of 1.3%[7] - The company's cash and cash equivalents increased to HKD 7,716,000 from HKD 3,722,000, reflecting a growth of 107.1% year-over-year[7] - The total equity rose to HKD 61,361,000, a significant increase from HKD 18,589,000 in 2022, marking a growth of 230.5%[7] - As of December 31, 2023, the group's net asset value increased to HKD 61,400,000 from HKD 18,600,000 as of December 31, 2022, representing an increase of HKD 42,800,000[98] Business Operations - The company has terminated its construction services business, focusing on medical product sales and plastic mold sales moving forward[8] - The company plans to closely monitor loan collections and implement strict cost control measures to optimize operational efficiency[11] - The company continues to evaluate its business segments independently due to the different products and services offered, which require distinct business strategies[18] - The company plans to focus on developing high-quality medical products and expanding its service team to enhance competitiveness in the medical products market[79] Segment Performance - Total revenue from external customers for the year ended December 31, 2023, was HKD 34,333,000, with contributions from medical products (HKD 21,938,000), plastic products (HKD 635,000), and lending (HKD 11,760,000) [21] - The reported segment performance showed a profit of HKD 3,262,000 from medical products, while the plastic products segment incurred a loss of HKD 829,000, and the lending segment generated a profit of HKD 14,744,000 [21] - Revenue from medical products sales was HKD 21,938 thousand in 2023, down from HKD 54,422 thousand in 2022, a decrease of 59.7%[32] - The medical products segment achieved a profit of HKD 3,300,000 for the year ended December 31, 2023, compared to a loss of HKD 25,600,000 in the previous year, primarily due to the recognition of expected credit loss provisions in the prior year[50] Credit and Lending - The expected credit loss for lending was approximately HKD 5,500,000, significantly reduced from HKD 47,400,000 in the previous year, indicating improved credit management[85] - The company received 71 loan renewal applications, all of which were successfully approved, with loan amounts ranging from HKD 100,000 to HKD 10,000,000[86] - The largest receivable from a single borrower was approximately HKD 4,100,000, accounting for 5.0% of total receivables[86] Investment Strategy - The group plans to diversify its investment portfolio to reduce concentration and investment risks amid recent market volatility[93] - The group is committed to maintaining a diversified investment strategy to minimize potential financial risks while ensuring stable growth in traditional business[96] - The group will closely monitor the performance of its investment portfolio and make necessary adjustments based on market dynamics[96] Corporate Governance - The company has adhered to the corporate governance code as per the Hong Kong Stock Exchange rules throughout the fiscal year ending December 31, 2023[111] - The audit committee consists of three independent non-executive directors, ensuring compliance with accounting principles and internal controls[115] - The financial figures in the preliminary announcement are consistent with the draft annual consolidated financial statements, as verified by the auditor Privatco CPA Limited[116] Employee and Operational Management - The management team has extensive experience in the medical products industry, with some members having over 10 years of experience, which is crucial for the group's future growth[56] - The company provides training for both new and existing employees to ensure skilled labor in production processes[71] - The company collaborates closely with the sales team to ensure customer requirements are met effectively during product development[67]

Financial Performance - For the six months ended June 30, 2023, the Group's revenue was HK$23.3 million, a decrease of HK$1.7 million or 6.8% from HK$25.0 million in the same period last year[6]. - Gross profit for the Group was HK$4.9 million, down HK$2.2 million or 31.0% compared to HK$7.1 million for the same period last year, with a gross profit margin of 21.1%, a decrease of 7.2 percentage points from 28.3%[7]. - The overall loss attributable to owners of the Company was HK$29.7 million, a slight decrease of HK$0.5 million from a loss of HK$30.2 million in the corresponding period of 2022[14]. - Revenue for the six months ended June 30, 2023, was HK$23,259,000, a decrease of 7.0% from HK$25,030,000 in the same period of 2022[116]. - Gross profit for the period was HK$4,906,000, down 30.7% from HK$7,071,000 year-on-year[116]. - Loss before income tax for the period was HK$29,673,000, slightly improved from a loss of HK$30,201,000 in the previous year[116]. - The Group reported a total segment loss of HK$10,445,000 for the six months ended June 30, 2023, compared to a loss of HK$11,390,000 for the same period in 2022, indicating an improvement in performance[144][150]. Revenue Breakdown - Revenue from the Medical Products Business decreased by HK$0.6 million or 3.5% to HK$16.4 million, accounting for 70.4% of the Group's total revenue[15]. - Revenue from the Plastic Products Business decreased by HK$0.6 million or 50.0% to HK$0.6 million, representing 2.7% of the Group's total revenue[21]. - Revenue from the Building Contract Works Business decreased by HK$1.0 million or 76.9% to HK$0.3 million for the six months ended 30 June 2023, contributing 1.1% of the Group's total revenue[25]. - The Medical Devices Business generated revenue of HK$16,380,000, while the Plastic Moulding Business contributed HK$635,000, and the Building Contract Works Business brought in HK$250,000 for the first half of 2023[144]. Expenses and Costs - Administrative expenses decreased by HK$11.6 million to HK$10.1 million, a reduction of 53.5% compared to HK$21.7 million in the same period last year[12]. - Finance costs for the period were HK$1.4 million, down from HK$1.8 million in the same period last year[13]. - Staff costs, including directors' emoluments, amounted to HK$1,738,000 for the first half of 2023, significantly lower than HK$10,877,000 in the same period of 2022, indicating a reduction of 84.0%[166]. Investment and Financial Position - The Group's total investment in WLS was approximately HK$45.5 million, representing 1.4% equity interests in WLS[40]. - The carrying amount of the Group's interest in WLS was approximately HK$11.1 million, accounting for about 6.9% of the total assets of the Company[40]. - The outstanding principal and interest amount of loan receivables as of 30 June 2023 was HK$94.3 million, up from HK$90.1 million as of 31 December 2022[30]. - The Group's total cash and bank balances increased to approximately HK$10.8 million as of June 30, 2023, compared to HK$3.7 million as of December 31, 2022[58]. - The Group's consolidated net assets increased to approximately HK$36.5 million, up from HK$18.6 million as of December 31, 2022[49]. Share Capital and Rights Issue - The Group completed a rights issue on February 1, 2023, issuing 483,775,896 rights shares, with estimated net proceeds of approximately HK$46.5 million[51]. - Approximately 71.4% or HK$33.2 million of the net proceeds from the rights issue is intended for repayment of bond payables[53]. - The total authorized share capital as of June 30, 2023, is 80,000,000,000 shares amounting to HK$400,000,000[200]. - The issued and fully paid shares increased from 483,775,896 shares (HK$24,189,000) on January 1, 2023, to 967,551,792 shares (HK$48,378,000) by June 30, 2023[200]. Corporate Governance and Compliance - The Company has complied with all provisions of the Corporate Governance Code for the six months ended June 30, 2023, except for the combined roles of Chairman and Managing Director held by Mr. Zhang Hengxin[106][107]. - The Audit Committee, comprising three Independent Non-executive Directors, reviewed the accounting principles and practices adopted by the Group and discussed financial reporting matters for the six months ended June 30, 2023[112]. - The Company did not purchase, sell, or redeem any of its listed securities during the six months ended June 30, 2023[113]. Future Outlook and Strategy - The Group is actively exploring potential business opportunities to expand its customer base and product portfolio in the Medical Products Business[19]. - The Group intends to diversify its investment portfolio to reduce concentration and investment risks in light of market volatility[34]. - The Group will continue to focus on projects with higher margins and manage costs effectively to improve business results[28]. - The Group aims to maintain a diversified investment portfolio to minimize financial risks amid economic uncertainties[44]. - The Group will focus on optimizing its business portfolio and exploring new growth opportunities to maximize shareholder value[46].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於百慕達註冊成立之有限公司） （股份代號：630） 二零二三年中期業績公告 雋泰控股有限公司（「本公司」）董事會（「董事會」）欣然宣佈本公司及其附屬公司 截至二零二三年六月三十日止六個月的未經審核綜合業績。本公告列載本公司二 零二三年中期報告的全文，並符合香港聯合交易所有限公司證券上市規則（「上市 規則」）中有關中期業績初步公告附載的資料要求。 為及代表董事會 雋泰控股有限公司 主席兼董事總經理 張亨鑫 香港，二零二三年八月二十八日 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於百慕達註冊成立之有限公司） （股份代號：630） 有關截至二零二二年報之 補充公告 茲提述雋泰控股有限公司（「本公司」）截至二零二二年十二月三十一日止年度之 年報（「二零二二年報」）。除另行界定外，本公告所用詞彙與二零二二年報內所界 定者具相同涵義。 除二零二二年報中的董事會報告當中「購股權計劃」一節及綜合財務報表附註29 所披露的內容外，本公司欲提供以下有關購股權計劃的額外資料。 截至二零二二年一月一日及二零二二年十二月三十一日，根據計劃授權授出及根 據購股權計劃可發行的購股權總數分別為48,377,589份及48,377,589份。購股權計劃 並無設定服務提供者分項限額。 ...

Financial Performance - The total revenue of AMCO United Holding Limited decreased by HK$2.7 million or 3.8%, from HK$71.9 million in 2021 to HK$69.2 million in 2022[15]. - The loss for the year increased significantly to HK$104.3 million in 2022, compared to a loss of HK$18.1 million in 2021[7]. - The equity attributable to owners of the Company dropped to HK$18.6 million in 2022 from HK$114.8 million in 2021[7]. - The total assets decreased from HK$184.8 million in 2021 to HK$172.8 million in 2022[7]. - The current ratio declined from 2.3 in 2021 to 1.7 in 2022, indicating a decrease in liquidity[7]. - The total debt to total assets ratio increased from 0.4 in 2021 to 0.9 in 2022, reflecting higher leverage[7]. - The return on total assets was recorded at (60.3%) in 2022, compared to (9.8%) in 2021, indicating a significant decline in asset efficiency[7]. - The return on sales also worsened to (150.6%) in 2022 from (25.2%) in 2021, highlighting increased operational losses relative to revenue[7]. Business Segments Performance - Revenue from Medical Products was HK$54.4 million, a decrease of 4.1% or HK$2.3 million compared to HK$56.7 million in the previous year, representing 78.6% of the Group's total revenue[38]. - The Medical Products segment recorded a loss of HK$25.6 million for the year ended December 31, 2022, compared to a profit of HK$0.5 million in 2021, primarily due to the provision for expected credit loss[42]. - Revenue from the Plastic Products segment increased by 175% or HK$0.7 million to HK$1.1 million, but accounted for only 1.6% of the Group's total revenue[44]. - Revenue from the Building Contract Works Business decreased by HK$1.4 million or 34.1% to HK$2.7 million, contributing 3.9% of the Group's total revenue[48]. - The Building Contract Works segment achieved a gain of HK$42,000 for the year ended December 31, 2022, a significant improvement from a loss of HK$7.6 million in 2021, mainly due to reduced staff costs[50]. - The Group's Money Lending Business turned from profit to loss in the current year, while the Securities Investment segment recorded a profit[22]. Credit Risk and Provisions - The expected credit loss (ECL) provision was approximately HK$74.7 million, up from HK$14.4 million in 2021, reflecting a credit loss rate of 46.3%[37]. - The expected credit loss rate for receivables as of December 31, 2022, was 46.3%, up from 23.3% in 2021, reflecting increased credit risk amid the COVID-19 pandemic[39]. - The Group recognized net impairment losses of approximately HK$47.4 million due to expected credit losses, compared to approximately HK$9.1 million in 2021, indicating a significant increase in credit risk[58]. - To mitigate default risk, the Group has enhanced loan requirements, including the necessity for borrowers to provide asset or income proof[57]. Investment Strategy - The Group intends to adopt a prudent investment attitude and develop its investment strategy to improve capital usage efficiency and generate additional returns on idle funds[77]. - The Group plans to closely monitor the performance of its investment business in light of recent market volatility, aiming to reduce concentration and investment risks[77]. - The Group maintained a diversified investment portfolio to minimize financial risks and will assess the performance of investments regularly[86]. - The Group's investment strategy aims for sustained long-term returns while traditional business continues stable growth[87]. Corporate Governance - The Company has complied with all code provisions of the Corporate Governance Code throughout the year ended 31 December 2022[121]. - All Directors have confirmed full compliance with the Model Code for Securities Transactions during the year ended 31 December 2022[122]. - The Board consists of two Executive Directors and three Independent Non-executive Directors, ensuring a balanced governance structure[124]. - The Company has a commitment to maintaining high standards of corporate governance and shareholder accountability[121]. - The company has arranged liability insurance for directors and officers to cover costs incurred in the execution of their duties[156]. Board Composition and Meetings - The Board of Directors held two meetings during the year, with all members attending 100% of the meetings[129]. - The Nomination Committee is responsible for reviewing the structure, size, and diversity of the Board at least annually[170]. - The Nomination Committee evaluated candidates based on character, qualifications, skills, and diversity in line with the company's corporate strategy[175]. - The Audit Committee also conducted two meetings, with full attendance from its members[184]. - The Remuneration Committee held two meetings during the year, with all members attending[166]. Financial Management - The Group's total cash and bank balances amounted to HK$3.7 million as of December 31, 2022, a decrease of HK$1.0 million from HK$4.7 million as of December 31, 2021[92]. - The Group's gearing ratio increased to 277.1% as of December 31, 2022, compared to 25.8% as of December 31, 2021[93]. - The Directors prepared the financial statements for the year ended December 31, 2022, on a going concern basis[200].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於百慕達註冊成立之有限公司） （股份代號：630） 截至二零二二年十二月三十一日止年度之業績公告 業績 雋泰控股有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈，本公司及其附 屬公司（以下統稱為「本集團」）截至二零二二年十二月三十一日止年度經審核綜 合業績連同去年之比較數字如下。 綜合損益及其他全面收益表 截至二零二二年十二月三十一日止年度 二零二二年 二零二一年 附註 千港元 千港元 收入 5 67,159 71,891 銷售及服務成本 (52,442) (57,776) 毛利 14,717 14,115 其他收入及其他收益或虧損 6 (16,341) 680 分銷成本 (1,626) (718) 行政開支 (27,223) (14,789) ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於百慕達註冊成立之有限公司） （股份代號：630） 補充公告 有關截至二零二一年十二月三十一日止年度之年報 謹此提述雋泰控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）日期為 二零二二年三月三十一日及於二零二二年四月二十八日刊發於香港聯合交易所有 限公司及本公司網站之截至二零二一年十二月三十一日止年度之年報（「年報」）。 除另有界定者外，本公告所用之詞彙與年報所界定者具有相同涵義。 除年報所披露之資料外，本公司謹此向股東及公眾人士提供有關年報之額外資料 如下。 放貸 本集團的放貸業務由本公司之一間間接全資附屬公司建信財務有限公司（「建信財 務」，為香港法例第163章《放債人條例》項下香港的一名持牌放債人）經營。本集 團透過使用本集團的內部資源向客戶（包括個人、私營及上市公司）提供貸款賺取 利息收入。客戶通常自本集團的業務網絡及關係（包括但不限於客戶及供應商）轉 介而來。於向潛在客戶授出貸款前，本 ...

Revenue and Profitability - For the six months ended June 30, 2021, the Group's revenue increased by HK$2.1 million or 7.6% to HK$29.8 million compared to HK$27.7 million in the same period last year, primarily driven by the Medical Products Business[7]. - Gross profit rose by HK$1.2 million or 15.4% to HK$9.0 million, with a gross profit margin increase of 2.3 percentage points to 30.5% from 28.2% in the previous year[8]. - The Medical Products Business revenue surged by HK$7.9 million or 75.2% to HK$18.4 million, accounting for 61.6% of the Group's total revenue for the period[16]. - The overall loss attributable to owners of the Company decreased by HK$10.6 million or 89.8% to HK$1.2 million compared to a loss of HK$11.8 million in the same period of 2020[15]. - Revenue for the six months ended 30 June 2021 was HK$29,845,000, representing an increase of 7.8% compared to HK$27,668,000 for the same period in 2020[134]. - Gross profit for the same period was HK$9,089,000, up from HK$7,792,000, indicating a gross profit margin improvement[134]. - Loss for the period narrowed to HK$1,245,000 from HK$11,810,000 in the previous year, reflecting a significant reduction in losses[134]. - Total comprehensive loss attributable to owners of the Company was HK$2,004,000, compared to HK$11,810,000 in the prior year[134]. Business Segments Performance - The Plastic Products Business revenue increased by HK$2.8 million or 140% to HK$3.0 million, representing 10.1% of the Group's total revenue[23]. - Revenue from the Building Contract Works Business decreased by HK$8.9 million or 76.1% to HK$2.8 million for the six months ended 30 June 2021, contributing 9.4% of the Group's total revenue[26]. - The Money Lending Business recorded loan interest income of HK$5.6 million, an increase of HK$0.4 million or 7.7%, accounting for 18.9% of the Group's total revenue[30]. - Segment profit for the Medical Products Business increased to HK$0.4 million from HK$0.1 million in the previous year, reflecting improved sales orders[21]. - The segment loss for the Building Contract Works Business decreased by HK$2.0 million or 60.6% to HK$1.3 million for the six months ended 30 June 2021[26]. - The segment profit from the Money Lending Business amounted to HK$0.6 million, up from HK$0.4 million in the previous year[30]. - Medical Devices Business generated revenue of HK$18,380,000, while the Money Lending Business contributed HK$5,631,000 for the six months ended June 30, 2021[158]. - Reportable segment profit for the six months ended June 30, 2021, was HK$11,189,000, compared to a loss of HK$4,314,000 in the same period of 2020[178]. Financial Position and Liquidity - As of 30 June 2021, the Group's consolidated net asset was approximately HK$130.1 million, a decrease of approximately HK$2.0 million compared to HK$132.1 million as at 31 December 2020[55]. - The Group's current ratio and quick ratio were both 2.2 as of June 30, 2021, down from 3.8 as of December 31, 2020, reflecting a decline in liquidity[59]. - The outstanding principal and interest amount of loan receivables was HK$136.3 million as of 30 June 2021, slightly up from HK$135.5 million at the end of 2020[30]. - Cash and cash equivalents decreased to HK$3,830,000 as of 30 June 2021, down from HK$27,663,000 at the beginning of the year[143]. - The Group's gearing ratio was 22.0% as of June 30, 2021, compared to 22.7% as of December 31, 2020, indicating a slight decrease in leverage[59]. - The Group will focus on maintaining liquidity by effectively managing working capital and controlling costs amid economic uncertainties[49]. Cost Management - Distribution costs increased significantly by HK$3.42 million to HK$3.43 million, while administrative expenses decreased by HK$1.4 million or 7.7% to HK$16.8 million[14]. - Administrative expenses decreased to HK$16,788,000 from HK$18,199,000, showing cost control efforts[134]. - Staff costs, including directors' emoluments, amounted to HK$2,543,000 for the first half of 2021, down from HK$5,032,000 in 2020, reflecting a decrease of approximately 49.7%[186]. - The cost of services recognized as expenses decreased to HK$4,964,000 in 2021 from HK$10,360,000 in 2020, reflecting a decline of about 52%[186]. Investment and Market Strategy - The Group intends to diversify its investment portfolio to reduce concentration and investment risks in light of recent market volatility[36]. - The Group aims to optimize its business portfolio to adapt to changing business climates and explore potentially profitable opportunities for sustainable growth[53]. - The Group is focusing on streamlining and outsourcing business processes, implementing strict cost control, and exploring potential business opportunities to expand its customer base[21]. - The Group will continue to focus on tendering for higher-margin projects in both public and private sectors to improve business results[29]. Corporate Governance and Compliance - The company has complied with all code provisions of the Corporate Governance Code for the six months ended June 30, 2021[121]. - All directors confirmed full compliance with the Model Code for securities transactions during the six months ended June 30, 2021[121]. - The roles of Chairman and Managing Director are combined, with Mr. Zhang Hengxin holding both positions, which the company believes is in the best interest of shareholders[121]. Share Option Scheme - The Company adopted a Share Option Scheme on June 30, 2015, approved by shareholders, to grant share options as incentives for contributions to the Group[74]. - The maximum number of shares that may be issued upon exercise of all share options under the Share Option Scheme must not exceed 10% of the issued share capital on the date of approval[80]. - The Share Option Scheme is valid for ten years and will expire at the close of business on June 29, 2025[81]. - The Company was authorized to refresh the scheme mandate limit to issue a maximum of 241,887,948 share options under the Share Option Scheme at the annual general meeting held on June 29, 2021[82]. Future Outlook - The year 2021 is expected to remain challenging due to the impact of COVID-19 and economic slowdowns, prompting the Group to modify its business strategies accordingly[48]. - The Directors noted that the future performance of the Group's investments will be volatile and significantly affected by the overall economic environment and market conditions[45].

AMCO UNITED HOLDING LIMITED 雋泰控股有限公司 ANNUAL REPORT 2020 年 報 AMCO UNITED HOLDING LIMITED (Stock Code 股份代號 : 630) (Incorporated in Bermuda with limited liability)（於百慕達註冊成立之有限公司） ANNUAL REPORT 2020 年報 * For identification purposes only 僅供識別 Contents 目錄 | --- | --- | |------------------------------------------------|--------------------------| | FINANCIAL HIGHLIGHTS | 財務摘要 | | CORPORATE INFORMATION | 公司資料 | | CHAIRMAN'S STATEMENT | 主席報告 | | MANAGEMENT DISCUSSION AND ANALYSIS | 管理層討論及分析 | | PROFILE OF DIRECTORS ...

Financial Performance - For the six months ended June 30, 2020, the Group's revenue was HK$27.7 million, a decrease of HK$17.8 million or 39.1% from HK$45.5 million in the same period last year[5]. - Gross profit for the Group was HK$7.8 million, down HK$3.7 million or 32.3% compared to HK$11.5 million for the same period last year, with a gross profit margin increase of 2.9 percentage points to 28.2%[6]. - The overall loss attributable to owners of the Company was HK$11.8 million, a decrease of HK$4.7 million or 28.3% compared to a loss of HK$16.5 million in the same period last year[14]. - Loss before income tax for the six months ended June 30, 2020, was HK$12,150,000, an improvement from a loss of HK$16,463,000 in 2019[111]. - The company reported a net loss of HK$11,810 for the six months ended June 30, 2020, compared to a loss of HK$16,463 for the same period in 2019, indicating an improvement in performance[118]. Revenue Breakdown - The Medical Devices Business revenue decreased by HK$7.1 million or 40.2% to HK$10.5 million, accounting for 37.9% of the Group's total revenue[15]. - The Plastic Moulding Business revenue decreased by HK$0.2 million or 40.0% to HK$0.3 million, representing 0.9% of the Group's total revenue[22]. - The Building Contract Works Business generated revenue of HK$11.7 million, a decrease of HK$10.1 million or 46.3% compared to HK$21.8 million in the same period of 2019, contributing 42.3% of the Group's total revenue[27]. - Loan interest income from the Money Lending Business was HK$5.2 million, a decrease of HK$0.5 million or 8.8% from HK$5.7 million in the previous year, accounting for 18.9% of the Group's total revenue[33]. Cost Management - Distribution costs declined by HK$0.09 million to HK$0.01 million, a reduction of 90.0% over the corresponding period of 2019[13]. - Administrative expenses decreased by HK$4.9 million to HK$18.2 million, representing a decrease of 21.2% compared to HK$23.1 million in the same period last year[13]. - Staff costs, including salaries, wages, and other benefits, decreased to HK$5,032,000 in 2020 from HK$6,904,000 in 2019, a reduction of about 27.1%[166]. - Cost of inventories recognized as expenses decreased to HK$9,516,000 in 2020 from HK$13,822,000 in 2019, a decrease of approximately 31.5%[166]. - Cost of services decreased to HK$10,360,000 in 2020 from HK$19,971,000 in 2019, representing a reduction of about 48.2%[166]. Investment and Assets - The outstanding principal and interest amount of loan receivables as of June 30, 2020, was HK$119.1 million, down from HK$136.6 million as of December 31, 2019[33]. - As of June 30, 2020, the Group held 8 listed equity securities in Hong Kong with a fair value of HK$12.7 million[39]. - The Group's total cash and bank balances amounted to approximately HK$27.7 million as of June 30, 2020, which increased by HK$15.4 million compared to HK$12.3 million as of December 31, 2019[58]. - The Group's total assets amounted to HK$170,748, a decrease from HK$187,153 as of December 31, 2019, representing a decline of approximately 8.1%[116]. - The company’s non-current assets decreased from HK$5,664 to HK$2,728, a decline of approximately 52.1%[116]. Share Options and Dividends - The Board does not recommend the payment of an interim dividend for the six months ended June 30, 2020, compared to nil for the same period in 2019[62]. - The total number of shares available for issue under the Share Option Scheme is 577,287,948, representing approximately 28.18% of the total shares in issue as of August 31, 2020 (i.e., 2,048,879,481 shares)[91]. - The total outstanding share options at the end of the period amounted to 372,400,000, which is approximately 18.18% of the total shares in issue[90]. - The exercise price for the share options granted is set at HK$0.087, with an exercise period from May 4, 2020, to May 3, 2025[90]. Business Strategy and Future Outlook - The Group is actively exploring potential business opportunities to expand its customer base in both the Medical Devices and Plastic Moulding segments[22]. - The Group aims to diversify its investment portfolio to reduce concentration and investment risks due to recent market volatility[40]. - The Group will continue to implement prudent credit control procedures to balance business growth and risk management in its Money Lending Business[33]. - The Group will focus on effective management of working capital and cost control to maintain liquidity amid economic slowdown and market volatility[53]. - The company expects the performance of the Building Contract Works Business to improve in the second half of 2020 based on the latest information available[197]. Impairment and Goodwill - The impairment loss recognized during the period was HK$6,379,000, compared to HK$0 in the previous period[189]. - Goodwill related to the Building Contract Works Business was approximately HK$10,196,000, with impairment recognized for both June 30, 2020, and December 31, 2019[190]. - The impairment loss has been included in profit or loss under administrative expenses[197]. - Goodwill of approximately HK$67,362,000 related to the Medical Devices Business unit was fully impaired as of 31 December 2014 due to significant and continuous losses incurred in prior years[197].